» Articles » PMID: 33373925

Clinical Characteristics and Treatment Outcome of COVID-19 Patients with Stroke in China: A Multicenter Retrospective Study

Abstract

Objective: Previous studies mainly reported the clinical characteristics of novel coronavirus 2019 (COVID-19) infections, but the research on clinical characteristics and treatment outcomes of COVID-19 patients with stroke is still rare.

Methods: A multi-center retrospective study was conducted at 11 hospitals in 4 provinces of China, and COVID-19 patients with stroke were enrolled from February 24 to May 4, 2020. We analyzed epidemiological, demographic, and clinical characteristics of cases as well as the laboratory test results, treatment regimens and outcomes, and the clinical characteristics and therapeutic outcomes were compared between severe and nonsevere patients, and by age group, respectively.

Results: A total of 27 patients [mean age: 66.41 (SD 12.1) years] were enrolled. Among them, 9 (33.3%) were severe patients and 18 (66.7%) were nonsevere patients; 17 (63.0%) were female; 19 (70.4%) were aged 60 years and above. The most common symptoms were fever [19 (70.4%)], fatigue [12 (44.4%)] and cough [11 (40.7%)], respectively. Abnormal laboratory findings of COVID-19 patients with stroke included high levels of C-reactive protein [19 (73.1%)], D-dimer [14 (58.3%)], blood glucose [14 (53.8%)], fibrinogen [13 (50.0%)], and decreased lymphocytes [12 (44.4%)]. Comparing to nonsevere cases with stroke, severe patients with stroke were likely to be older, susceptible to receiving oxygen inhalation, and had more complications (p < 0.05). In addition, there were significant differences in lymphocytes, neutrophils, lactate dehydrogenase, C-reactive protein, creatine kinase between the severe cases and nonsevere cases (p < 0.05). The older patients had a decreased platelet count and elevated fibrinogen, compared with the younger (p < 0.05). All patients (100%) received antiviral treatment, 12 (44.4%) received antibiotics treatment, 26 (96.3%) received Traditional Chinese Medicine (Lung cleansing & detoxifying decoction), and oxygen inhalation was in 18 (66.7%). The median duration of hospitalization was 16 days. By May 4, 2020, a total of 26 (96.3%) patients were cured and discharged, and 1 (3.7%) patients died.

Conclusion: COVID-19 patients with stroke had poor indicators of coagulation system, and severe and older patients might have a higher risk of complications and unfavorable coagulation system. However, the overall treatment outcome is favorable.

Citing Articles

Recent advancements in traditional Chinese medicine for COVID-19 with comorbidities across various systems: a scoping review.

Shang X, Cao Y, Guo Y, Zhang L, Li J, Zhang H Infect Dis Poverty. 2024; 13(1):97.

PMID: 39696533 PMC: 11658301. DOI: 10.1186/s40249-024-01263-8.


Diagnosis and Treatment Protocol for COVID-19 Patients (Tentative 8th Edition): Interpretation of Updated Key Points.

Wang G, Zhao L, Wang X, Jiao Y, Wang F Infect Dis Immun. 2024; 1(1):17-19.

PMID: 38630067 PMC: 8057309. DOI: 10.1097/ID9.0000000000000002.


Epidemiology, pathogenesis, and management of Coronavirus disease 2019-associated stroke.

Liu L, Zhou C, Jiang H, Wei H, Zhou Y, Zhou C Front Med. 2024; 17(6):1047-1067.

PMID: 38165535 DOI: 10.1007/s11684-023-1041-7.


The Effect of Covid-19 Severity on Lower Urinary Tract Symptoms Manifestations.

Daryanto B, Janardhana A, Purnomo A Med Arch. 2022; 76(2):127-130.

PMID: 35774040 PMC: 9233460. DOI: 10.5455/medarh.2022.76.127-130.


Effect of Qingfei Paidu decoction combined with Western medicine treatments for COVID-19: A systematic review and meta-analysis.

Zhang L, Ma Y, Shi N, Tong L, Liu S, Ji X Phytomedicine. 2022; 102:154166.

PMID: 35636170 PMC: 9107386. DOI: 10.1016/j.phymed.2022.154166.


References
1.
Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

2.
Hu D, Zhu C, Ai L, He T, Wang Y, Ye F . Genomic characterization and infectivity of a novel SARS-like coronavirus in Chinese bats. Emerg Microbes Infect. 2018; 7(1):154. PMC: 6135831. DOI: 10.1038/s41426-018-0155-5. View

3.
Li K, Wohlford-Lenane C, Perlman S, Zhao J, Jewell A, Reznikov L . Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. J Infect Dis. 2015; 213(5):712-22. PMC: 4747621. DOI: 10.1093/infdis/jiv499. View

4.
Connors J, Levy J . COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135(23):2033-2040. PMC: 7273827. DOI: 10.1182/blood.2020006000. View

5.
Wichmann D, Sperhake J, Lutgehetmann M, Steurer S, Edler C, Heinemann A . Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med. 2020; 173(4):268-277. PMC: 7240772. DOI: 10.7326/M20-2003. View